Long-term clinical and biologic effects of the lipidosterolic extract ofSerenoa repens in patients with symptomatic benign prostatic hyperplasia
Authors:
- 1 November 2002
- journal article
- clinical trial
- Published by Springer Nature in Advances in Therapy
- Vol. 19 (6) , 297-306
Abstract
Permixon®, the lipidosterolic extract ofSerenoa repens, is widely used for the treatment of symptoms associated with benign prostatic hyperplasia (BPH). This open study assessed the efficacy and tolerability of Permixon 160 mg twice daily administered for 2 years. One hundred fifty-five men with clinically diagnosed BPH and complaints of prostatic symptoms were enrolled in the study. At 6, 12, 18, and 24 months, the International Prostate Symptom Score (I-PSS), quality of life, and sexual function score were recorded, and urodynamics and biologic values were measured. Adverse events were recorded every 3 months. I-PSS and quality of life improved significantly from baseline at each evaluation time point. At the end of the study and at each evaluation, maximum urinary flow also improved significantly. Prostate size decreased. Sexual function remained stable during the first year of treatment and significantly improved (P = .001) during the second year. Prostate-specific antigen was not affected, and no changes in plasma hormone levels were observed. Nine patients reported 10 adverse events, none related to treatment. Improvements in efficacy parameters began at 6 months and were maintained up to 24 months. These data demonstrate the long-term efficacy and tolerability of Permixon and support its use as a first-line medical therapy for uncomplicated symptomatic BPH.Keywords
This publication has 22 references indexed in Scilit:
- Reproducibility and Clinical and Concurrent Validity of the MSF-4: A Four-Item Male Sexual Function Questionnaire for Patients with Benign Prostatic HyperplasiaValue in Health, 2001
- A Meta-Analysis on the Efficacy and Tolerability of α1-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic ObstructionEuropean Urology, 1999
- Saw Palmetto Extracts for Treatment of Benign Prostatic HyperplasiaJAMA, 1998
- Long-Term Effects of Finasteride in Patients with Benign Prostatic Hyperplasia: A Double-Blind, Placebo-Controlled, Multicenter StudyUrology, 1998
- Serenoa repens (Permixon®)Drugs & Aging, 1996
- Phytotherapy for the prostateBritish Journal of Urology, 1996
- The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic HyperplasiaNew England Journal of Medicine, 1996
- Tamsulosin, a selective α 1c ‐adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH)British Journal of Urology, 1995
- Alpha-Blockade in the Treatment of Symptomatic Benign Prostatic HyperplasiaJournal of Urology, 1995
- Human prostatic steroid 5α-reductase isoforms—A comparative study of selective inhibitorsThe Journal of Steroid Biochemistry and Molecular Biology, 1995